Medication Review: Laboratory Monitoring Recommendations for Guselkumab in PSO, PsA, and IBD

February 2026

In this Medication Review, Lisa Asfahani, PA-C, shares practical laboratory monitoring recommendations for guselkumab across psoriasis, psoriatic arthritis, and inflammatory bowel disease. The discussion reviews FDA-approved indications, dosing basics, and what labs to check before and after initiating therapy, including TB screening and liver function monitoring. This overview offers clear, real-world guidance to support safe and effective use of IL-23 inhibition in clinical practice. Visit RhAPP.org, the RhAPP Content Rheum or the RhAPP ACE 2.0 app for more rheumatology education and resources.